Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Autor: Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Rafaella, Arcangeli, Giuseppina, Corallo, Salvatore, Delliponti, Laura
Předmět:
Zdroj: BMC Cancer; 5/6/2024, Vol. 24 Issue 1, p1-2, 2p
Abstrakt: This document is a correction notice for an article published in BMC Cancer. The authors reported an error in the funding section of their article and provided the correct funding statement. The study is an investigator-driven trial sponsored by Gruppo Oncologico del Nord Ovest and funded by GONO Foundation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, and Fondazione Anna Villa e Felice Rusconi Onlus. The project is also in collaboration with Intesa Sanpaolo S.p.A. The study will be conducted according to current regulations. Springer Nature, the publisher, remains neutral with regard to jurisdictional claims and institutional affiliations. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje